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Abstract 
Background: The in vitro production of mature human red blood cells (RBCs) from induced pluripotent stem cells 
(iPSCs) has been the focus of research to meet the high demand for blood transfusions. However, limitations like high 
costs and technological requirements restrict the use of RBCs produced by iPSC differentiation to specific circum‑
stances, such as for patients with rare blood types or alloimmunized patients. In this study, we developed a detailed 
protocol for the generation of iPSC lines derived from peripheral blood of donors with O D‑positive blood and rare 
blood types (D–and Jr(a‑)) and subsequent erythroid differentiation.
Methods: Mononuclear cells separated from the peripheral blood of O D‑positive and rare blood type donors were 
cultured to produce and expand erythroid progenitors and reprogrammed into iPSCs. A 31‑day serum‑free, xeno‑free 
erythroid differentiation protocol was used to generate reticulocytes. The stability of iPSC lines was confirmed with 
chromosomal analysis and RT‑PCR. Morphology and cell counts were determined by microscopy observations and 
flow cytometry.
Results: Cells from all donors were successfully used to generate iPSC lines, which were differentiated into erythroid 
precursors without any apparent chromosomal mutations. This differentiation protocol resulted in moderate erythro‑
cyte yield per iPSC.
Conclusions: It has previously only been hypothesized that erythroid differentiation from iPSCs could be used to 
produce RBCs for transfusion to patients with rare blood types or who have been alloimmunized. Our results dem‑
onstrate the feasibility of producing autologous iPSC‑differentiated RBCs for clinical transfusions in patients without 
alternative options.
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Background
Since the 17th century, the transfusion of red blood cells 
(RBCs) has been a crucial part of modern medicine, ena-
bling the alleviation of symptoms in patients with severe 
anemia or trauma. Currently, RBCs are only available 
from donations by healthy volunteers, but insufficient 
numbers of donors and the potential for transfusion-
transmitted infections remain considerable challenges 
in meeting the demand for blood [1–3]. Despite exten-
sive efforts, it is not always easy to find a suitable blood 
component, and alternative systems capable of transport-
ing oxygen to the body have been evaluated, including 
perfluorochemical-based RBC substitutes, hemoglobin-
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However, these blood substitutes result in insufficient 
oxygen delivery and an increased likelihood of death [5], 
and therefore are not promising alternatives [6].
During the past decade, enormous progress has been 
made in the ex vivo manufacture of human RBCs [7–11]. 
Hematopoietic stem cells (HSC) obtained from cord 
blood and bone marrow have been used to produce func-
tional enucleated RBCs [12–16]. There have been numer-
ous advances in the generation of safe erythroid cells and 
improvements in the efficiency of single hematopoietic 
cell acquisition by differentiation of CD34 + HSCs using 
cytokines and small molecules [9, 17–28]. As human 
HSCs are a limited resource and ethical concerns hinder 
the use of embryonic HSCs, the large-scale expansion of 
RBCs for transfusion purposes remains problematic.
Induced pluripotent stem cells (iPSCs) are an essen-
tially infinite source of stem cells owing to their self-
renewal ability. Since the first report of these cells in 
2006, human iPSCs have been derived from many cell 
types, including blood cells [29–32]. The original proto-
col, which involved the integration of transcription factor 
combinations into the cell genome, has been refined and 
now makes use of integration-free factors, which make 
iPSCs therapy for regenerative medicine applications 
safer [33]. Although the current methods for manipu-
lating iPSCs are extremely inefficient and costly, iPSCs 
have certain benefits such as immortality, the lack of allo-
genic immune reactions, and the lack of ethical concerns 
on destruction of human embryos; therefore, studies of 
iPSC-derived RBC production are ongoing. An ideal 
strategy is to generate autologous RBCs using iPSCs, but 
the process is not feasible in clinical settings owing to the 
long time required for supplying the manufactured blood 
for transfusion and high cost of production.
Irrespective of the number of blood donors, main-
taining an all-inclusive supply of transfusable blood for 
the broad population is challenging, particularly owing 
to alloimmunized individuals or those with rare blood 
types. Thirty blood group systems and over 300 RBC 
alloantigens have been identified, but most alloantibod-
ies belong to the Rh, Kell, Duffy, Kidd, and MNS blood 
group systems [34]. The development of “universal” RBCs 
applicable to the entire population has been slow [35]. A 
study by the French National Registry of People with a 
Rare Blood Phenotype/Genotype suggested that 15 iPSC 
lines are sufficient to manage nearly all alloimmunized 
patients [36].
Blood banks have difficulty in finding suitable blood 
components for patients with rare blood types such as 
Jr(a-) and Dphenotypes.  Jra is an extremely high-inci-
dence antigen seen in all populations. The incidence 
of Jr(a-) phenotype is only 0.03 to 0.12 percent even in 
Japanese population, which has been noted to have the 
highest frequency of Jr(a-) individuals worldwide   [37]. 
D–phenotypes are characterized by red blood cells 
not expressing RHCE protein at their plasma mem-
brane, which leads to absence of C, c, E, and e antigens. 
Although this phenotype can be found in various popula-
tions, it is very rare with frequencies estimated at 0.001 
percent in Japanese population [38]. Therefore, the use 
of iPSCs prepared from patients with rare blood types to 
obtain RBCs has been considered [39–42], but empirical 
evidence for the effectiveness and safety of this approach 
are lacking.
In this study, we constructed a registry of iPSC lines 
from peripheral blood samples collected from donors 
with the O D-positive and rare blood group phenotypes. 
We devised a detailed protocol for generating iPSCs from 
peripheral blood mononuclear cells (PB-MNCs) and dif-
ferentiating them into functional RBCs.
Materials and methods
Study design and cell sources
After receiving consent from patients and donors, blood 
was collected from five O D-positive donors and from 
two patients with rare blood types, D–and Jr(a-). RBC 
antigenic phenotypes were determined by using mono-
clonal RBC antibody reagents (Ortho-Clinical Diagnos-
tics, Raritan, NJ, USA). The H9 human embryonic stem 
cell line (WiCell, Madison, WI, USA) was used as a con-
trol. This study was approved by the Institutional Review 
Board of Yonsei University Severance Hospital, Seoul, 
Korea (IRB No. 4-2016-1158).
Generation of induced pluripotent cell lines
Isolation of pb‑mncs from whole blood
Peripheral blood (10–15 mL) was drawn into a tube con-
taining sodium heparin anticoagulant (BD Biosciences, 
Oxford, UK). PB-MNCs were purified using either 
Ficoll–Paque Premium (GE Healthcare, Uppsala, Swe-
den) or Lymphoprep (Stem Cell Technologies, Oslo, Nor-
way). Viable PB-MNCs were counted by the trypan blue 
exclusion method (Trypan Blue Stain 0.4%; Gibco, Life 
Technologies, Carlsbad, CA, USA) [43].
Expansion of erythroid progenitors
To stimulate the growth of erythroid precursors, via-
ble PB-MNCs were resuspended at a density of 1 × 106 
cells/mL in erythroid expansion medium, composed 
of basal medium and erythroid cytokines. The rea-
gents used for cell cultures have been listed in Table  1. 
The basal medium was prepared by adding 150  μg/mL 
transferrin (Sigma-Aldrich, Gillingham, UK), 50  μg/
mL insulin (Sigma-Aldrich), 90  ng/mL ferrous nitrate 
(Sigma-Aldrich), 160  μM monothioglycerol (Sigma-
Aldrich), and 1% penicillin–streptomycin (Gibco) in 
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Stemline II medium (Sigma-Aldrich). The erythroid 
expansion medium was prepared by adding 1 μM hydro-
cortisone (Sigma-Aldrich), 100  μg/mL stem cell fac-
tor (Sigma-Aldrich), 6  IU/mL erythropoietin (StemCell 
Technologies, Vancouver, Canada), and 10 μg/mL inter-
leukin 3 (Peprotech EC Ltd., London, UK) to the basal 
medium. If there were excess PB-MNCs, the surplus 
cells were frozen with either Cryostar (BioLife Solutions, 
Bothell, WA, USA) or mFreSR (StemCell Technologies).
MNCs (1 × 107) were suspended in 10 mL of erythroid 
expansion medium in a 25T (Nunc EasYFlask Cell Cul-
ture Flask, Cat# 156367; Thermo Scientific, Waltham, 
MA, USA) flask and cultured for 3  days in a 5%  CO2 
incubator at 37 °C. After 3 days, both non-adherent and 
adherent cells were recovered, and the cells were resus-
pended at a density of 1 × 106 cells/mL in fresh erythroid 
expansion medium. From day 7, morphological analyses 
were performed daily until the population of erythroid 
progenitor cells accounted for more than 80% of the total 
PB-MNCs. When the population of erythroid progenitor 
cells reached 80% or higher, the cells were ready to be 
transfected. The erythroid enrichment step can be pro-
longed to obtain more erythroid progenitor cells in fresh 
erythroid expansion medium.
Reprogramming of expanded erythroid progenitors
Before transfection, each well in a 6-well multidish 
(Nunc Cell-Culture Treated Multidish, Cat#140675; 
Thermo Scientific) was coated with a mixture of 14.5 μL 
of Matrigel Matrix (Corning, Kennebunk, ME, USA) and 
985.5  μL of DMEM/F12 (1 ×) (Gibco) for 1  h at 25  °C. 
A total of 1 × 106 culture-expanded erythroid cells were 
centrifuged (400×g, 5 min) and resuspended in 104 μL of 
medium (18 μL of supplement 1, 82  μL of nucleofector 
solution (both from the P3 Primary Cell 4D-Nucleofactor 
Kit, Lonza Amaxa), 2  μL of Epi5 Episomal Reprogram-
ming Vectors, and 2  μL of Epi5 p53 and EBNA vectors 
(both from the Epi5 Episomal iPSC Reprogramming 
Kit; Life Technologies, Frederick, MD, USA) at 25  °C 
for 10  min. Prepared cells were transferred to a 100-μL 
Table 1 List of reagents used for cell culture
Materials Abbreviations Company Catalogue#
Bone morphogenetic proteins 4 BMP4 Peprotech 120‑05
Vascular endothelial growth factor VEGF Peprotech 100‑20
Wnt3A Peprotech 315‑20
Activin A Peprotech 120‑14E
GSK‑3β Inhibitor VIII Calbiochem 361549
Fibroblast growth factor alpha FGFa Peprotech 100‑17A
β‑Estradiol Sigma‑Aldrich E2257
Insulin‑like growth factor 2 IGF2 Peprotech 100‑12
Thrombopoietin TPO Peprotech 300‑18
Heparin StemCell Technologies 07980
3‑Isobutyl‑1‑methylxanthine IBMX Sigma‑Aldrich I5879
StemRegenin 1 SR1 Cellagen Technology C7710
Hydrocortisone HC Sigma‑Aldrich H0888
Stem cell factor SCF Peprotech 300‑07
Interleukin 3 IL‑3 Peprotech 200‑03
Erythropoietin EPO Stem Cell 02625
Poloxamer 188 P188 Sigma‑Aldrich P5556
Transferrin TF Sigma‑Aldrich T8158
Insulin Sigma‑Aldrich I3536
Ferric nitrate FN Sigma‑Aldrich F8508
Monothioglycerol MTG Sigma‑Aldrich M6145
Penicillin–Streptomycin P‑S Gibco 15140122
Y‑27632 StemCell Technologies 72392
Stemline II hematopoietic stem cell expansion 
medium
Sigma‑Aldrich S0192
mTeSR1 basal medium StemCell technologies 85851
mTeSR1 5 × Supplement StemCell technologies 85852
AggreWell EB formation medium StemCell technologies 05893
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Nucleocuvette Vessel (Lonza, Koln, Germany) and loaded 
on the 4D-Nucleofector System (Lonza). Electrotransfec-
tion under the ‘CD34 cell, human cell type’ program as 
per the manufacturer’s instructions (https ://biosc ience 
.lonza .com/lonza _bs/US/en/downl oad/produ ct/asset 
/30292 ). After removing the cuvette, the processed cells 
were transferred to 6 mL of erythroid expansion medium, 
mixed well, and plated at a density of 3.3 × 105 cells per 
well (i.e., 2 mL of the cell suspension) on a Matrigel pre-
coated 6-well plate.
Each well was supplemented with 1  mL of erythroid 
expansion medium on post-transfection day (PT-D) 2, 
and with 1  mL of ReproTeSR Basal Medium (Stem Cell 
Technologies) on PT-D3 and PT-D5. From PT-D7, com-
plete medium changes were performed with 2  mL of 
ReproTeSR daily, and the cultures were close observed 
until colonies with an iPSC-like appearance were 
observed. Typically, iPSC-like colonies appeared after 
PT-D14. The colonies were manually picked based on 
their morphology between PT-D14 and PT-D24 under a 
polarizing microscope, and each colony was passaged as 
individual iPSC lines thereafter.
Maintenance of induced pluripotent stem cells
Human iPSC cultures were maintained on plates coated 
with 40  μL of Vitronectin XF (Stem Cell Technologies) 
and 1 mL of CellAdhere Dilution Buffer (Stem Cell Tech-
nologies) for 1 h in 2 mL of mTESR1 medium (mTeSR1 
5 × Supplement 1:4 mTeSR1 Basal medium; Stem Cell 
Technologies). All cells were cultured at 37 °C in a humid-
ified atmosphere containing 5%  CO2 and were cultured 
daily with mTESR1 media until reaching 80–90% conflu-
ence. The cells were typically ready for passage within 5 
to 7 days. For the newly reprogrammed iPSCs (i.e., up to 
passage 3), colonies were mechanically passaged using a 
drawn-out glass Pasteur pipette to dissociate individual 
colonies. This method is used for passaging only desired 
undifferentiated iPSC colonies, and not unwanted differ-
entiated colonies. From passage 3, iPSCs were enzymati-
cally passaged using ReLeSR (Stem Cell Technologies). 
Medium was changed daily, and cells were subcultured 
once every 5 to 7 days.
Differentiation into erythrocytes
Generation of embryoid bodies (EB) (Fig. 1)
On differentiation day (DD) 0, EBs were formed on 
AggreWell 400 plates (Stem Cell Technologies) accord-
ing to the manufacturer’s instructions (https ://cdn.stemc 
ell.com/media /files /manua l/MA291 46-Repro ducib 
le_Unifo rm_Embry oid_Bodie s_Using _Aggre Well_Plate 
s.pdf ). AggreWell plates were pre-treated with 2  mL 
of AggreWell Rinsing Solution to remove any bubbles 
lodged within the wells (centrifugation at 2000×g, 5 min). 
Single cells were derived from the monolayer culture 
of iPSCs by enzymatic treatment with Easy Gentle Cell 
Dissociation Reagent (Stem Cell). Approximately 2 × 106 
single cells were seeded into each well of the AggreWell 
plate with 5  mL of AggreWell EB Formation Medium 
(Stem Cell Technologies) containing 10  μM Y-27632 
(Stem Cell Technologies). Cell aggregation was achieved 
by centrifugation at 100 × g for 3 min.
On DD1, EBs from each well of the AggreWell plate 
were transferred to a 6-well multi-dish with Stemline II 
medium containing 5  ng/mL bone morphogenic pro-
tein 4 (BMP4), 5  ng/mL vascular endothelial growth 
factor (VEGF), 2.5  ng/mL Activin A, 5  ng/mL Wnt3A, 
and 0.5 μl/ml GSK3β inhibitor VIII. Cells were plated at 
5 × 105 cells per well.
On DD3, a new set of cytokines was added to the 
existing culture volume along with 0.5  mL of Stemline 
II medium per well. Cytokines were added at a 6× con-
centration to supplement the entire volume such that 
the final concentrations in the well (assumed volume, 
3 mL) were 20 ng/mL BMP4, 30 ng/mL VEGF, 10 ng/mL 
Wnt3A, 5 ng/mL Activin A, 2 mM GSK3β inhibitor VIII, 
10 ng/mL acidic fibroblast growth factor (FGFa), 20 ng/
mL stem cell factor (SCF), and 0.4 ng/mL β-estradiol.
Differentiation towards hematopoietic stem cell lineage 
(Fig. 2)
On DD4, EBs were harvested, washed in DPBS, and dis-
sociated using TrypLESelect × 10 (Gibco, Thermo Sci-
entific) for 10 min at 37  °C. The cells were resuspended 
in fresh Stemline II medium and plated at 2 × 105 cells 
per well of a standard six-well tissue culture plate with 
the following factors: 20 ng/mL BMP4, 30 ng/mL VEGF, 
10  ng/mL FGFa, 30  ng/mL SCF, 10  ng/mL insulin-like 
growth factor 2, 10  ng/mL thrombopoietin, 5  μg/mL 
heparin, 50 mM isobutylmethyl xanthine, and 0.4 ng/mL 
β-estradiol.
On DD6, the differentiation factors from DD4 were 
refreshed by adding 0.5  mL Stemline II medium per 
well with a 6× concentration of cytokines and StemRe-
genin (1 mM) was added. On DD8, cells were subjected 
to a complete medium change with DD4 factors. If the 
cell count was greater than 5 × 105 cells/mL, the culture 
was split, and the density was reset to 2 × 105 cells/mL to 
support proliferation. On DD9, half of DD4 factors were 
added in 0.5 mL of Stemline II medium per well.
Differentiation towards erythroid precursors and maturation
On DD11, the cells were replated in erythroid liquid 
culture conditions. The cells were plated at a density of 
3 × 106 cells per well in 3 mL of basal medium with the 
following cytokines: 1  μM HC, 100  ng/mL SCF, 10  ng/
mL IL-3, and 6  IU/mL EPO. On DD14, the cells were 
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Fig. 1 The scheme of the production of human induced pluripotent stem cells from peripheral blood. After isolating the PB‑MNCs using 
Ficoll‑Paque, cells are enriched in erythroid expansion medium for 7 days to stimulate the growth of erythroid precursors. When erythroid 
progenitor cells reach 80% of the total PB‑MNCs, cells are transfected with reprogramming vectors (Oct4, Sox2, Lin28, Klf4, and L‑Myc)
Fig. 2 Diagram representing the feeder‑free and serum‑free erythroid differentiation of iPSCs. Abbreviations: BMP, bone morphogenic protein; EB, 
embryoid body; EPO, erythropoietin; FGF, fibroblast growth factor; HC, hydrocortisone; iPSC, induced pluripotent stem cells; IBMX, isobutylmethyl 
xanthine; IGF, insulin‑like growth factor; IL, interleukin; SCF, stem cell factor; TPO, thrombopoietin; VEGF, vascular endothelial growth factor
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subjected to a complete medium change with DD11 
factors. On DD18, the cells were replated at a density 
of 3 × 106 cells per well in 3  mL of basal medium with 
the following cytokines: 50  ng/mL SCF, 10  ng/mL IL-3, 
and 3  IU/mL EPO. On DD21, medium was completely 
replaced with DD18 factors. On DD24, the cells were 
replated at a density of 3 × 106 cells per well in 3 mL of 
basal medium with the following cytokines: 50  ng/mL 
SCF, 2 IU/mL EPO, and 0.05% poloxamer 188. On DD27, 
the cells were replated at a density of 3 × 106 cells per well 
in 3 mL of basal medium with 0.05% P188.
Detection of transfected reprogramming factor genes
Total RNA from iPSCs was isolated using the RNeasy 
Plus Mini Kit (Qiagen, Hilden, Germany). Two micro-
grams of total RNA were used for reverse transcription 
reaction using the SuperScript III First Strand (Invitro-
gen, Thermo Scientific) according to the manufacturer’s 
instructions. Quantitative real-time RT-PCR (qRT-PCR) 
was performed using qPCR TaqMan probes (Applied 
Biosystems) and Step One Plus (Applied Biosystems, Fos-
ter City, CA, USA). All experiments were performed in 
duplicate, and a non-template control (lacking the cDNA 
template) was included in each assay. Gene expression 
levels were normalized relative to levels of endogenous 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
and relative expression was calculated using the ΔΔCT 
method  [44].
The following qPCR TaqMan probes (Applied Bio-
systems) were used: POU5F1(OCT4) Hs04260367_
gH_FAM; NANOG Hs02387400_g1_FAM; SOX2 
Hs01053049_s1_FAM; KLF4 Hs00358836_m1_
FAM; c-MYC Hs00153408_m1_FAM; GAPDH 
Hs02758991_g1_VIC.
Immunocytochemistry assay
Reprogrammed cells were fixed in 4% paraformaldehyde 
(Tech & Innovation, Gangwon-do, Korea) for 20 min at 
room temperature, washed twice with DPBS, and per-
meabilized with 0.2% Triton X-100 (Sigma-Aldrich) for 
15 min at room temperature. The cells were blocked for 
1 h with 5% donkey serum in DPBS. Samples were incu-
bated at room temperature for 1 h with primary antibod-
ies against stage-specific embryonic antigen 4 (SSEA4), 
octamer-binding transcription factor 4 (OCT4), sex-
determining region Y-box  2 (SOX2), TRA-1-60, and 
NANOG homeobox (NANOG) (all from Human Embry-
onic Stem Cell Marker Panel, Abcam, Cambridge, UK) 
(Table  2). Secondary antibodies, either Alexa Fluor 594 
anti-rabbit or Alexa Fluor 488 anti-mouse antibodies 
(Life Technologies, Eugene, OR, USA), were incubated 
at room temperature for 1  h. The nuclei were stained 
with 4′6-diamidino-2-phenylindole (VYSIS, Down-
ers Grove, IL, USA). Cells were visualized under a fluo-
rescence microscope (CKX53; Olympus, Tokyo, Japan) 
with an Olympus U-RFL-T fluorescence lamp. Image 
Table 2 List of antibodies used for immunocytochemistry or flow cytometry
APC, allophycocyanin; Cat, catalogue; FITC, fluorescein isothiocyanate; PE, phycoerythrin
Antibodies used for immunocytochemistry
Marker type Antibody Company, Cat#





Secondary antibodies Alexa Fluor 594 donkey anti‑rabbit IgG Life Technologies, Cat# A‑21207
Alexa Fluor 488 goat anti‑mouse IgG Life Technologies, Cat# A‑11001
Antibodies used for flow cytometry
Embryonic stem cell markers PE mouse anti‑human TRA‑1‑60 BD Biosciences, Cat# 560193
FITC mouse anti‑human SSEA4 BioLegend, Cat# 330410
Differentiation markers FITC mouse anti‑human CD34 BD Biosciences, Cat# 555821
APC mouse anti‑human CD43 BD Biosciences, Cat# 560198
PE mouse anti‑human CD235a BD Biosciences, Cat# 555570
APC mouse anti‑human CD71 BD Biosciences, Cat# 551374
Isotype control FITC mouse IgG BioLegend, Cat# 401306
PE mouse IgM BD Biosciences, Cat# 555584
APC mouse IgG BD Biosciences, Cat# 555751
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analysis and colocalization studies were performed using 
Ocular Image Acquisition Software (OCULAR, ver-
sion 2.0.1.496; Digital Optics Limited, Auckland, New 
Zealand).
Flow cytometric analysis
At DD0, human iPSCs were analyzed by flow cytom-
etry for investigating the expression of the pluripotency 
markers SSEA4 and TRA-1-60 (BD Biosciences). iPSCs 
were dissociated using Gentle Cell Dissociation Rea-
gent (Gibco, Thermo Scientific) and aliquots of 1 × 105 
cells/200 μL (0.5  M EDTA, pH 8.0, 1:90 DPBS) were 
prepared. Conjugated antibodies (10  μL/105 cells) were 
added to the cells and incubated on ice for 30 min in the 
dark. Unbound antibodies were removed by washing the 
cells with 900  μL of DPBS, centrifugation at 160×g for 
5 min, and decanting the supernatant. Cells were resus-
pended in 400 μL of 4% paraformaldehyde (Tech & Inno-
vation) for preservation up to 3 days.
At DD4, 11, 18, and 24, cells were analyzed by flow 
cytometry to evaluate their hematopoietic and erythroid 
characteristics. TrypleSelect × 10 (Gibco, Thermo Sci-
entific) was used to dissociate the cells, if they were not 
evenly dissociated. Preparation procedures were identical 
to those used for DD0.
All antibodies used for flow cytometry have been listed 
in Table 2. The BD FACSVerse Flow Cytometer (BD Bio-
sciences) and FlowJo (version 10.2, FlowJo, LLC, Ash-
land, OR, USA) were used for the analysis. Nonspecific 
immunoglobulin isotype controls of the corresponding 
class served as negative controls. Compensation beads 
were used to modify compensation matrixes.
Analysis of chromosomal abnormalities
The cells were fixed and examined by a standard G-band-
ing chromosome analysis [45]. The analysis was per-
formed by GenDix, Seoul, Korea. For each cell line, 20 
metaphase cells were analyzed.
Morphological analysis
Cells (1 × 105 cells per slide) were immobilized onto a 
glass microscope slide using a cytocentrifuge (Cytospin 
4, Thermo Scientific; 800  rpm, 3  min) and stained with 
Wright-Giemsa dye (Sigma-Aldrich) for observation.
Results
Establishment of iPSCs generated from PB‑MNCs
The production of hiPS cell lines from peripheral blood 
samples involved the following three steps: erythroblast 
enrichment, electrotransfection, and iPSC initiation. In 
the erythroblast enrichment step, the cells were trans-
fected when the erythroblast population exceeded 80% 
(Fig.  3). Typically, cells were ready for transfection on 
day 7 of the enrichment step as the erythroblast popula-
tion presenting both CD235a and CD71 antigens usually 
exceeded 80% by day 7, but if the cells were not ready the 
enrichment step was prolonged for couple more days. 
When the erythroblast percentage was between 40% and 
50%, the enrichment step was prolonged for 2 to 3 days 
before transfection.
After transfection, iPSC colony isolation took 
7–21 days (mean, 16 days), and individual variation was 
observed in colony formation efficiency with a yield of 
4–10 colonies per 1 × 106 MNCs. The feeder-free transfer 
method was used for passaging established cell lines. The 
reprogramming efficiency was quite low (0.001%), but all 
cultures resulted in the formation of some iPSC colonies.
Characterization of the stemness of iPSCs generated using 
episomal vectors
The stemness of iPSCs was verified using iPSC colonies 
from passages 8–10. Chromosomal analyses, qRT-PCR, 
flow cytometry analysis, and immunocytochemical stain-
ing of iPSCs were performed for 5 O D-positive subjects 
and 2 subjects with rare blood (Fig.  4). We established 
that iPSCs generated from rare blood types using our 
protocol behave similarly in culture and colony mor-
phologies to those of H9 or O D-positive controls. A 
chromosomal analysis of all peripheral blood iPSC colo-
nies showed a normal karyotype. Quantitative RT-PCR 
showed expression of transfected reprogramming fac-
tor genes. By flow cytometry analysis, single cells were 
shown to express pluripotency markers TRA-1-60 and 
SSEA4. Immunocytochemistry assay revealed that iPSC 
clones retained the typical characteristics of pluripotent 
stem cells, including the expression of embryonic stem 
cell markers (e.g., OCT4, SOX2, NANOG, TRA-1-60, 
and SSEA4). These data demonstrated the pluripotency 
of the iPSCs.
Differentiation of banked iPSCs into erythroid lineage cells
Erythroid cell morphology developed over time dur-
ing the differentiation cultures (Fig.  5a). A shift from a 
relatively large proportion of hematopoietic precursor 
cells (HPCs) to differentiated erythroid precursors were 
observed between DD4 and DD24; during this time, the 
population shift was evident by flow cytometry analysis 
(Fig.  5b). The cumulative change in cell number from 
iPSCs to differentiated cells after 24  days were between 
8 and 18-folds (Fig.  5c). Jr(a-) and H9 cell lines showed 
similar amplification curves until DD15, and then Jr(a-) 
showed accelerated proliferation reaching up to 17-folds 
by DD24, whereas H9 stopped at nine-folds. In contrast, 
D– cell line showed accelerated growth in the beginning 
of the differentiation protocol, and the final cumulative 
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folds for rare blood groups were similar on DD24, which 
were higher than that of the H9 cell line.
Using flow cytometry, the markers of HSCs (CD34 and 
CD43), early erythroid progenitors (CD71), and mature 
erythroid cells (CD235a) were detected (Fig. 5d). Antigen 
presentation for each cell lines varied, but some common 
characteristics could be found. CD34 + CD43 + HSC 
population was observed in H9 cell lines on DD11, but 
CD34 antigen was not observed in any of the rare blood 
type cell lines. In all cell lines, early HPCs expressing 
CD43 were detected from DD11 onwards [46]. Most 
HSCs were differentiated into HPCs, whereas HPCs were 
observed throughout the duration of the differentiation 
protocol, with a decrease in CD34 and high frequency of 
CD43. CD71, which is selectively expressed at high lev-
els not only in erythroid precursors but also in all prolif-
erating cells [47], was strongly expressed in all erythroid 
precursors and even in HSCs. The mature erythroid 
cell marker, CD235a was prominently observed after 
DD18 and peaked on DD24, which were more readily 
observed in H9 and Jr(a-) cell lines. Generally, the order 
of antigenic profile for the differentiated cells were CD71, 
followed by CD43 with or without presence of CD34, and 
finally CD235a + CD71 high population.
Discussion
Extensive studies have evaluated the differentiation of 
iPSCs into erythrocytes as a possible strategy to meet the 
demand for blood components [7, 8, 11]. Various proto-
cols have been developed all of which follow the same 
basic steps: iPSC generation by incorporating pluripotent 
genetic factors, self-renewal and expansion of the iPSCs, 
and differentiation into erythroid lineage cells, which 
includes commitment, expansion, and maturation [27, 
31, 48–50]. Many studies have focused on specific parts 
of the protocol, but relatively few studies have evalu-
ated the entire process, starting from iPSC generation to 
erythroid differentiation.
Finding suitable starting population for growing 
RBCs has been a challenge. The main source materi-
als to produce RBCs in  vitro are hematopoietic stem/
progenitor cells, embryonic stem cells, and iPSCs [51]. 
Fig. 3 Counting erthyroblast cells to determine the date for transfection: a separated PB‑MNCs were enriched with cytokines adequate for 
promoting erythroid progenitors. Typically, erythroblast population exceeded 80% on expansion day 7. b flow cytometry analysis of 7‑days enriched 
erythroid progenitors presenting CD235a and CD71 antigens. c On erythroblast expansion day 7, if the observed erythroblast population (blue 
arrow) was less than 80%, transfection was performed after extending the expansion step for 2–3 days in the same conditions
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Fig. 4 Stemness characterization of iPSCs generated from normal donor (N‑001 ~ N‑005) and patients with rare blood type (Jr(a‑), D–): a 
chromosomal analysis showed normal karyotypes for all cell lines, b quantitative reverse transcription polymerase chain reaction revealed 
successful transfection of reprogramming factor genes, c flow cytometric analysis and d immunocytochemistry assay indicated that each cell line 
expressed embryonic stem cell markers (SSEA4, TRA‑1‑60, NANOG, SOX4, and OCT4)
Fig. 5 Characteristics of erythroid lineage cells differentiated from donor iPSCs: a photographs of Wright‑Giemsa staining of cytospin preparations 
at different stages of the differentiation protocols at days 3, 10, 17, and 24 for Jr(a‑) cell line. b shift in population of cultured Jr(a‑) cells from 
hematopoietic stem and precursor cells to erythroid precursors. c growth kinetics of H9, Jr(a‑), and D– cell lines measured as cumulative fold 
change. d chronological shift of CD markers of each cell line (blue) and isotype control (red) as assessed by flow cytometry
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The major advantage of iPSCs over other source materi-
als is that they can be produced from any type of cells, 
both immature and mature cells without causing ethi-
cal concerns arisen by using human embryos [52]. Our 
experiment used PB-MNCs as the starting population 
for iPSCs because reprogrammed iPSCs may retain epi-
genetic memory inherited from the parental cells. There-
fore, using hematopoietic cells were preferable to other 
sources such as fibroblasts.
Assuming that efficient in  vitro large-scale cultured 
RBC production will be possible in the near future, the 
banking of iPSC clones may be a key strategy for provid-
ing iPSC-derived RBCs. Based on this approach, our lab-
oratory has started to build a registry of iPSC clones from 
many O D-positive and O D-negative donors. By con-
firming that the antigen profiles of donor RBCs match 
those of differentiated RBCs, we believe that it is possible 
to create a registry suitable for nearly 100% of the Korean 
population with a handful of iPSC lines. There are few 
exceptions where autologous transfusions are needed, 
such as in the case of patients with rare blood types or 
alloimmunized patients receiving multiple transfusions, 
hence separate registry including these rare patients are 
required.
In this study, PB-MNCs from two patients with rare 
blood types (Jr(a-) and D–) were successfully used to 
generate iPSCs and differentiated into RBCs. The detailed 
protocol described in this research encompasses the 
entire process in a detailed manner, from the expansion 
of PB-MNCs and generation of iPSCs by transfection of 
episomal vectors, maintenance of iPSCs, and differentia-
tion into erythroid lineage cells. Furthermore, this pro-
cess makes use of our serum-free, xeno-free protocol 
which is compatible with the Good Manufacturing Prac-
tice (GMP). The use of autologous iPSC-derived RBCs 
from patients with rare blood types has been described in 
theory; however, to the best of our knowledge, this is the 
first report of banking rare blood type iPSCs for produc-
ing GMP-grade erythrocytes.
The major limitations for the clinical application of 
iPSC-derived RBCs are the inefficient RBC enucleation, 
difficulty of switching to adult-type globin, and the sub-
stantial number of RBCs  (1012) needed to generate 1 unit 
of transfusable RBCs. Our protocol suffered from simi-
lar limitations, therefore the use of other small molecules 
and cytokines should be explored to overcome these hur-
dles [22–24]. Prior to using iPSC-derived RBCs clinically, 
further investigations are needed including: evaluation 
of RBC antigen profile, additional evaluation of iPSCs 
for genomic mutations, testing of the RBCs in agglutina-
tion assays, and/or safety testing of the RBCs in animal 
models. Lastly, in this study each cell line was differenti-
ated into erythroid cells only once. Replicate experiments 
must be performed to make this protocol more robust 
and eliminate any variabilities.
Recently published articles deal with similar limitations 
and tries to find novel methods using modified cytokine 
mixtures and microenvironments. To produce GMP 
grade transfusable RBCs, many researchers are removing 
animal or human derived substances from prior proto-
cols [53, 54]. Although it may be more costly and ineffi-
cient so far, xeno- and feeder-free methods are necessary 
to reduce possible side effects of manufactured RBCs 
when transfused to patients. Use of bioreactors, modi-
fying microenvironments using macrophages and small 
molecules, and utilizing genetic alterations are currently 
being developed to enhance survival of mature RBCs, 
increase enucleation rate, and promote hemoglobin 
switching  [54–57].
Conclusions
In conclusion, our findings demonstrate the feasibility 
of building a registry of iPSC clones from O D-positive 
donors and patients with rare blood types using a care-
fully developed serum-free, xeno-free protocol. The 
development of banked iPSCs for both research and clin-
ical applications is an important step in the advancement 
of personalized medicine, and in fulfilling the need to 
establish specialized stem cell registry dedicated to RBC 
transfusions.
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